Dabholkar N et al., 2021-08-10: Review arguing that methylene blue can address both oxidative and cytokine components of COVID-19, and compiling the clinical reports. A review, with no new data.
However, both the drugs have low efficacy because they cannot inhibit the production of free radicals and cytokines at the same time.
Dabholkar N et al., 2021-08-10: Review arguing that methylene blue can address both oxidative and cytokine components of COVID-19, and compiling the clinical reports. A review, with no new data. Study type: narrative review. N/A. Country: India. MB dose discussed as <2 mg/kg for safety; routes and doses of the reviewed studies vary. Funding/conflicts: authors declare none. Comparator: none. States MB "has been approved by the US FDA for the treatment of other diseases" , true only for methemoglobinemia. The anti-cytokine claim is mechanistic, not demonstrated in a controlled trial. Also filed as MTL-059 (claims C11, C4). Study type: review.
